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Abstract
AIM: To compare clinical success and complications of 
uncovered self-expanding metal stents (SEMS) vs cov-
ered SEMS (cSEMS) in obstruction of the small bowel.
METHODS: Technical success, complications and 
outcome of endoscopic SEMS or cSEMS placement in 
tumor related obstruction of the duodenum or jeju-
num were retrospectively assessed. The primary end 
points were rates of stent migration and overgrowth. 
Secondary end points were the effect of concomitant 
biliary drainage on migration rate and overall survival. 
The data was analyzed according to the Strengthening 
the Reporting of Observational Studies in Epidemiology 
guidelines.
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RESULTS: Thirty-two SEMS were implanted in 20 pa-
tients. In all patients, endoscopic stent implantation 
was successful. Stent migration was observed in 9 of 
16 cSEMS (56%) in comparison to 0/16 SEMS (0%) 
implantations (P = 0.002). Stent overgrowth did not 
significantly differ between the two stent types (SEMS: 
3/16, 19%; cSEMS: 2/16, 13%). One cSEMS dislodged 
and had to be recovered from the jejunum by way of 
laparotomy. Time until migration between SEMS and 
cSEMS in patients with and without concomitant biliary 
stents did not significantly differ (HR = 1.530, 95%CI 
0.731-6.306; P = 0.556). The mean follow-up was 57 
± 71 d (range: 1-275 d).
CONCLUSION: SEMS and cSEMS placement is safe in 
small bowel tumor obstruction. However, cSEMS is ac-
companied with a high rate of migration in comparison 
to uncovered SEMS.
© 2013 Baishideng. All rights reserved.
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Core tip: Gastrointestinal obstruction is a complica-
tion of advanced cancer disease. It heavily impacts on 
patients’ general condition. Endoscopic implantation 
of self-expanding metal stents (SEMS) is a safe and 
established procedure for palliative treatment of tumor 
obstruction. Covered SEMS are considered favorable 
concerning reobstruction by inhibiting tumor ingrowth. 
In contrast, uncovered SEMS might harbor a lower 
risk of migration and dislocation. In the present study 
covered SEMS were retrospectively compared with un-
covered SEMS in patients with small bowel or duodenal 
obstruction. Significantly higher migration rates were 
observed in the covered SEMS group without observing 
significant increase of the rate of patients with tumor 
ingrowth indicating that uncovered SEMS should be carcinomatosis. Histology was obtained by endoscopic 
biopsy from the intestinal tumor or percutaneous needle 
biopsy from liver metastasis. The therapeutic procedures 
were ascertained in an interdisciplinary conference with 
senior physicians from the departments of surgery, gas-
troenterology and medical oncology and the recommen-
dation to treat by endoscopic stent placement was given 
in consent.
We retrospectively reviewed the prospectively collect-
ed records on technical success of the procedure, clinical 
benefit, and the incidence of complications including 
migration and stent occlusion. The patients’ outcome at 
follow-up was additionally registered.
Patients were advised to resume oral intake of liquids 
within 24 h and to advance to a low-residue diet as toler-
ated. The status of oral food intake was monitored at 
one-month intervals on an outpatient basis. In case of 
recurrence of dysphagia, radiographic imaging (iodine or 
barium upper gastrointestinal series) and/or upper gas-
trointestinal endoscopy was performed. Patients who had 
recurrent symptoms caused by tumor overgrowth were 
treated by placement of a second intestinal stent.
Endoscopic technique and stent selection
Stents were placed by very experienced gastroenterologi-
cal endoscopists using a therapeutic gastroscope (GIF-
1TQ 160), or a duodenoscope (TJF-Q180V, TJF-160 
VR; all Olympus medical Europe, Hamburg, Germany) 
with a working channel of 3.7 or 4.2 mm, respectively. 
All stents were inserted through-the-scope (TTS) in 
combination with over-the-wire technique, and all stents 
were placed under fluoroscopic guidance. Selection of 
SEMS vs cSEMS was at the appraisal of the endoscopist 
and cSEMS was preferably chosen in case of advanced 
tumors with subtotal or complete obstruction intend-
ing to avoid later tumor ingrowth. SEMS was preferred 
over cSEMS in case that the investigator was in fear of 
blocking biliary outflow by crossing the duodenal papilla 
by the stent. If complications (migration or overgrowth) 
occurred, new stents were placed and the stenting proce-
dure in the patient was switched from a covered to an un-
covered stent and vice versa. The stents used in this study 
were self-expandable Nitinol uncovered SEMS (Niti-S, 
D-Type, TaeWoong medical, South Korea) and covered 
SEMS [cSEMS; Niti-S pyloric duodenal covered stent 
(End Bare Type), TaeWoong medical, South Korea]. A 
stent diameter from 18 to 28 mm and a stent length from 
40 to 120 mm were used. The cSEMS provides a silicone 
covering and has a retrieval suture for preventing tumor-
ingrowth and easy removal. It contains a fixed-cell braid-
ed structure. The SEMS is a fine mesh tubular prosthesis 
that facilitates immediate and continuous wall apposition 
due to the so-called D-weaving technology, i.e., stent cells 
are unfixed resulting in a high flexibility and retaining its 
shape even in bending sections of the intestinal tract. In 
case that a stent did not cover the entire tumor obstruc-
tion, two overlapping stents were implanted to bridge the 
entire obstructed bowel segment and this was accounted 
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favored for palliative treatment of tumor obstruction of 
the duodenum or the small bowel.
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INTRODUCTION
Endoscopic placement of self-expandable metal stents 
(SEMSs) has become a broadly accepted first line treat-
ment option for patients with advanced malignant in-
testinal stenosis. Reconstitution of the intestinal transit 
is paramount in palliation of tumor obstruction, and 
endoscopic SEMS insertion is weighed against surgical 
intervention in terms of clinical relief, complication rate, 
and length of hospital stay of the patient. In the small 
bowel, duodenal tumor obstruction has increasingly been 
treated by SEMS placement
[1,2], but SEMS insertion in the 
lower small bowel is less often performed
[3,4]. Duodenal 
SEMS insertion is technically feasible in more than 90% 
of interventions; it is safe and comes along with a faster 
start of oral intake, shorter length of hospital stay, lower 
morbidity and probably reduced in-hospital mortality as 
compared to surgical treatment
[5-13]. SEMS may as well be 
preferred over surgical treatment in the lower small bowel 
and at anastomotic small bowel obstructions in case of 
recurrent malignancy
[4].
Tumor in- or over-growth can limit long-term out-
come of SEMS in 12% to 21% of cases, but stent occlu-
sion might be reduced by covering the SEMS with sili-
cone or plastic membranes (covered SEMS, cSEMS)
[1,2].
Aim of this study was to compare outcome of SEMS 
vs cSEMS in small bowel tumor obstruction and to iden-
tify technical feasibility, safety, clinical impact, complica-
tions and patient’s outcome at follow-up.
MATERIALS AND METHODS
All patients who underwent endoscopic placement of 
SEMS or cSEMS for small bowel tumor obstruction (du-
odenum or jejunum) between August 2009 and Septem-
ber 2012 were retrospectively analyzed. Due to advanced 
or metastatic disease or comorbidity, none of the patients 
were considered candidates for curative surgical treatment 
of the tumor. All patients included into this study were 
symptomatic and were admitted to the hospital because 
of their obstructive symptoms including nausea, vomit-
ing, bloating, or abdominal pain. At least for some time 
all patients were suffering from postprandial vomiting. 
No patient was treated for non-symptomatic stenosis. In-
dication for jejunal placement of stents was only given in 
cases of unilocular stenosis by circumscribed peritoneal as a single application in this study.
Definition
Tumor overgrowth of the stent was defined as deteriora-
tion of the patient’s condition (recurrence of dysphagia) 
and detection of narrowing of the stent lumen within or 
adjacent to the proximal or distal end of the stent mesh as 
a result of tumor growth, as shown by endoscopic and/or 
radiologic findings. Tumor ingrowth was defined as tumor 
obstruction through the stent mesh as a reason for as de-
terioration of the patient’s condition (recurrence of dys-
phagia). Improvement of vomiting or the intake of fluids 
or food was assessed qualitatively. Postinterventional com-
plication rate was defined as occurrence of complications 
within 24 h after stent placement, all other complications 
were observed until the end of the follow-up period.
Ethics
The retrospective study was approved by the institutional 
review board (Ethikkomission) of the Johann Wolfgang 
Goethe-University Hospital.
Statistical analysis
The present study is a retrospective cohort study. The 
primary endpoints were complications due to stent 
implantation including tumor overgrowth and stent mi-
gration. The secondary end points were effect of con-
comitant biliary stenting on migration rates and overall 
survival. Statistical analyses were performed with SPSS 
(Version 22.0, IBM, NY, United States). Predictors of 
survival were determined using a univariate Cox regres-
sion hazard model. Death was recorded as event. Survival 
curves with the estimated hazards where calculated with 
the Cox regression model. The patients at risk at the indi-
vidual time points are shown in the figures. The data was 
analyzed according to the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines
[14]. 
RESULTS
Thirty-two cases of stent insertion were included in this 
study: 16 cSEMSs and 16 SEMSs were placed in 20 pa-
tients. Patient characteristics are shown in Table 1. Five 
patients received two overlapping stents; in the remaining 
27 interventions a singular stent was put in place. Where-
as all covered SEMS were implanted in the duodenum, 3 
of 16 uncovered SEMS were inserted into the jejunum. 
The main etiology of gastric outlet obstruction was pan-
creatic cancer, followed by cholangiocellular carcinoma or 
gallbladder carcinoma (Table 1). All three jejunal SEMS 
were placed due to an obstruction that was caused by a 
circumscribed manifestation of peritoneal carcinomatosis 
in gastric cancer patients. Nine of the SEMS (56%) and 
eight of the cSEMS (50%) were placed in patients who 
presented with concomitant biliary tract stenosis; all these 
patients were treated with placement of plastic stents or 
SEMS/cSEMS into the common bile duct (CBD), and 
plastic endoprosthesis were replaced by biliary SEMS at 
the time of duodenal SEMS insertion in all patients.
We observed technical success of SEMS placement 
in all cases without occurrence of peri-interventional 
complications. In three (SEMS) and two (cSEMS) stent 
placements, respectively, balloon dilatation was needed 
for complete expansion of the stents. The duration of 
endoscopic procedure did not significantly differ between 
SEMS and cSEMS (Table 2). The clinical condition ame-
liorated in 14 of 16 (87.5%) cases treated with SEMS and 
intake of fluids or food improved. In contrast, in patients 
treated with cSEMS the clinical condition improved in 12 
of 16 (75%) cases only. However, this difference was not 
statistically significant (P = 0.564).
The mean follow-up time ± SD was 57 ± 71 d with a 
range of 1-275 d. In patients with gastric outlet obstruc-
tion and concomitant biliary obstruction no migration 
or occlusion of the bile duct stents was observed. Nine 
of the 16 cSEMS (56%) migrated within the observation 
time. In one of the patients the dislodged stent had to be 
recovered from the jejunum by laparotomy. The patient 
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Table 1  Patients' characteristics  n (%)
Characteristics SEMS cSEMS
Stents 16 (50) 16 (50)
Male gender   7 (44) 10 (63)
Age (yr), mean ± SD (range)   70 ± 11 (50-85)   71 ± 11 (50-84)
Localization
   Jejunum, n    3   0
   Duodenum, n 13 16
Disease
   Pancreatic carcinoma, n   6   7
   Cholangiocellular carcinoma, n   3   2
   Gallbladder carcinoma, n   1   2
   Gastric cancer, n   3   2
   Colorectal cancer, n   2   0
   Breast cancer metastasis, n   1   0
   Stenosis due to duodenal ulcer 
   perforation, n
  0   3
Balloon dilatation of the stent   3 (19)   2 (13)
Concomitant biliary drainage    9 (56)   8 (50)
SEMS: Self-expanding metal stent; cSEMS: Covered SEMS.
Table 2  Complications  n (%)
Complications SEMS cSEMS P value
Duration of procedure 
(min), median (range)
          60 (40-121)           60 (31-160) 0.867
Migration    0 (0)      9 (56) 0.002
Time until migration (d), 
mean ± SD (range)
- 30 ± 52 (1-161) NA
Tumor overgrowth      3 (19)      2 (13) 0.725
Tumor ingrowth, n 0 0 NA
Time until tumor 
overgrowth (d), 
mean ± SD (range)
143 ± 95 (39-224) 96 ± 105 (22-170) 0.572
Overall survival (d), 
median, range
        40 (3-275)           75 (11-426) 0.431
NA: Not available; SEMS: Self-expanding metal stent; cSEMS: Covered 
SEMS.
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variate Cox regression model (Figure 3B).
DISCUSSION
In this comparative study, we observed a high rate (> 
50%) of stent migration in the covered SEMS group in 
comparison to the non-covered SEMS group (0%) in 
palliation of duodenal or small bowel obstruction. Con-
currently, technical feasibility of stent placement (TTS 
technique) was similar, and relief of symptoms was equal 
in both patient groups. Insertion of SEMS was as safe 
as cSEMS implantation during periinterventional sur-
veillance of the patient. Thereby, biliary SEMS did not 
prevent migration of duodenal cSEMS migration, and 
the migration rate in patients with and without concomi-
tant biliary stents was similar. We did not observe clini-
cally significant tumor ingrowth in the SEMS or cSEMS 
group. However, the overall survival times were quite 
short and in patients with longer survival times cSEMS 
might show advantages concerning tumor ingrowth rates.
Randomized trials comparing SEMS vs cSEMS treat-
ment in the small bowel has not been reported up to 
date, but an increased risk of stent migration in covered 
SEMS has been reported in colonic tumor palliation: 
Stent migration was four times as common in the covered 
SEMS group as in the non-covered stent group in a re-
cent meta-analysis
[15]. In patients with inoperable gastric 
cancer, comparison of cSEMS vs SEMS yielded similar 
results: Migration was observed in 26.0% of patients, in 
comparison to 2.8% in non-covered SEMS in a random-
ized trial
[16]. Our results suggest that migration rate in the 
small bowel is even higher than in the stomach or large 
bowel. Technical success rate and clinical success was 
similar in cSEMS vs SEMS in both studies, and immediate 
complications were near to zero. Migration rates are low 
(1%-3% of cases) in other studies reporting on SEMS 
insertion in the duodenum and small bowel
[1,17].
As the duration of the endoscopic treatments and the 
responsible endoscopists did not differ between the two 
cohorts, we consider two factors to contribute mainly on 
migration in cSEMS vs SEMS study: First, the stent cover 
minimizes hyperplastic tissue to get hold of the stent 
was dismissed from hospital treatment after recovery 
from the surgery. On the contrary none of the SEMS 
dislocated. SEMS placement was superior to cSEMS for 
duodenal location of obstructions concerning migra-
tion rate (0% vs 56%). However, although none of the 
three SEMS placed in the jejunum migrated within time 
no further conclusion can be drawn for a superiority of 
SEMS in the jejunal location as no cSEMS was placed in 
the jejunum. The mean time until migration ± SD was 30 
± 52 d with a range of 1-161 d.
As stents in situ of the CBD might give hold to the 
duodenal SEMS/cSEMS and might be associated with a 
reduced rate of stent migration, we analyzed the group 
of patients with CBD SEMS/cSEMS and concomitant 
duodenal SEMS/cSEMS placement separately. In 17 of 
32 cases, a combined biliary and duodenal SEMS/cSEMS 
insertion had been undertaken. Comparing the time until 
migration of stents in patients with and without biliary 
SEMS/cSEMS, there was no difference in migration of 
duodenal stents (HR = 1.530, 95%CI: 0.731-6.306; P = 
0.556). In those 17 patients in whom a biliary SEMS was 
in place, all six events of stent migration were observed 
in patients with duodenal cSEMS, whereas no migration 
was seen in patients with uncovered duodenal SEMS (P = 
0.008). A representative example of duodenal stent with 
concomitant biliary metal stent implantation is shown in 
Figure 1.
Overgrowth of a SEMS by progressive cancer oc-
curred in three cases, whereas this complication was 
seen in two of the cSEMS patients. There was no tumor 
ingrowth into any of the stents (SEMS or cSEMS) ob-
served. In case of tumor overgrowth or migration, a new 
stent was placed into the stenosis and migrated cSEMS 
were replaced by uncovered SEMS. A flow chart demon-
strating the algorithm of stent treatment is displayed in 
Figure 2.
Thirteen patients died within the observation time. 
The median overall survival was 74 d (Figure 3A). To as-
sess the influence of the stent type on survival, overall 
survival times for the two kinds of stents were compared. 
There was no significant difference between SEMS and 
cSEMS concerning overall survival according to a uni-
A B C
Figure 1  Self-expanding metal stents insertion in duodenal tumor obstruction. A: Retention of secretions and food in the stomach; B: Duodenal self-expanding 
metal stents (SEMS) together with biliary SEMS in X-ray; C: SEMS in endoscopic imaging.
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mesh and partial ingrowth of tumorous and hyperplastic 
tissue is prevented, thus minimizing any anti-migration 
effect that the stent may provide against the natural mo-
tility of the small bowel. Moreover, we think that the 
fixed-cell braided structure of the SEMS we used might 
have significantly contributed to migration by causing 
the stent to straighten itself by use of its axial expansion 
force. In opposite, the so-called D-weaving technology 
of the SEMS with unfixed stent cells might have resulted 
in a higher flexibility and retention of its shape even 
at bending sections of the intestinal tract, such as the 
duodenum. The motility of the small bowel contributes 
to the progression of the stent. Stent migration can be 
reduced by endoscopic clip fixation of stents in the duo-
denal position
[18]. This procedure might be impracticable 
and only short-lasting, though, as clips usually dislodge in 
the short term.
The use of SEMS in duodenal obstruction might be 
compromised by concomitant biliary obstruction. How-
ever, combined endoscopic treatment is safe and success-
ful in the majority of cases with only minor complica-
tions (0%-16% of cases)
[19-23] even if others report found 
much higher incidence of complications (up to 52%)
[24]. 
In our cohort of patients there were no treatment related 
complications of biliary drainage by duodenal stents. 
Migration rates were also not affected by the existence 
of biliary stenting. However, all events of migration of 
duodenal stents in patients receiving combined biliary 
and duodenal stenting happened in patients who had 
obtained cSEMS. Therefore, biliary stenting may protect 
from duodenal stent migration, if the biliary stents are 
placed in between the meshes of uncovered SEMS. The 
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Figure 3  Survival curves. A: The overall survival curve calculated with the 
Cox regression model; B: Survival curves for self-expanding metal stents 
(SEMS) and covered SEMS (cSEMS) placements calculated with the Cox re-
gression model.
Figure 2  The treatment algorithm for self-expanding metal stents placement. SEMS: Self-expanding metal stents; cSEMS: Covered SEMS.
Tumor obstruction (n = 32)
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at follow-up (n = 4)
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growth (n = 3)
Migration 
(n = 0)
SEMS (n = 1)
cSEMS (n = 2)
Tumor over-
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advantage of SEMS in comparison to cSEMS might 
be lower rates of tumor occlusion
[1,2,19]. In contrast in 
patients receiving cSEMS recurrence of tumor occlu-
sion is rarely observed
[19]. The rate of stent occlusion 
did not significantly differ between patients with SEMS 
(19%) and cSEMS (13%) in our study, though. Also in 
another report no differences were found between SEMS 
and SEMS concerning necessity of re-interventions
[25]. 
An overview of literature concerning complications of 
SEMS placements is provided in Table 3.
The limitation of the current study is the retrospec-
tive non-randomized approach. However, in conclusion, 
technical feasibility, tumor overgrowth, and overall sur-
vival of the patients are comparable in SEMS vs cSEMS, 
but migration rate is much higher in cSEMS as migration 
was observed in none of the SEMS group patients. 
We prefer SEMS over cSEMS insertion as first choice 
for malignant duodenal and small bowel obstruction and 
restrict use of cSEMS in cases with fast tumor ingrowth. 
Prospective randomized trials are needed to compare 
SEMS and cSEMS for small bowel obstruction.
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Canena et al
[32] 74, 80 Endoscopic stenting for gastric outlet obstruction   9.5%   0.0% 1.4% 0.0%
Cha et al
[33] 85, 85 Endoscopic stenting for gastroduodenal obstruction 29.0%   4.0% 4.0% 4.0%
Own data 20, 32 Small bowel/duodenum cSEMS 13.0%
SEMS 19.0%
cSEMS 56.0%
SEMS 0.0%
0.0% 0.0%
SEMS: Self-expanding metal stent; cSEMS: Covered SEMS; NM: Not mentioned.
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